Regenerative medicine

Ocul Immunol Inflamm. 2025 Oct;33(8):1794-1798. To report the successful use of internal limiting membrane peeling, inverted flap and plasma rich in growth factors in bilateral full-thickness macular hole in Behçet's disease.

Biomed Pharmacother. 2025 Oct:191:118440. Posterior segment diseases are a leading cause of irreversible blindness and remain challenging to treat with current therapies. Blood-derived products have emerged as promising regenerative tools due to their anti-inflammatory, neuroprotective, and regenerative properties. This review synthesizes evidence from 46 clinical studies published between 2019 and 2025, covering 1253 patients and 1570 eyes treated with platelet-rich derivatives for ocular fundus diseases. The most frequent indications were structural defects (59 %), inherited retinal dystrophies (11 %), optic neuropathies (11 %), age-related macular degeneration (7 %), and vascular dysfunctions (5 %). These therapies were administered via various routes, including intravitreal, subtenon, suprachoroidal, and subretinal injections, as well as eye drops and fibrin membranes.

Fertil Steril. 2025 Sep;124(3):496-505. To investigate the association of autologous platelet-rich plasma (PRP) treatment with functional ovarian reserve parameters and in vitro fertilization (IVF) outcomes of poor ovarian responders and women with primary ovarian insufficiency (POI) who refused oocyte donation.

Ophthalmol Ther. 2025 Sep;14(9):2253-2281. Immunosafe plasma rich in growth factors eye drops (is-ePRGF) have shown anti-inflammatory and regenerative effects on ocular surface diseases (OSD). However, medical or technical issues may preclude some patients from undergoing autologous blood extraction. We aimed to evaluate the safety and clinical outcomes of allogeneic is-ePRGF therapy for refractory OSD in real-world practice.

Aging (Albany NY). 2025 Jun 27;17(6):1571-1580. The study assesses the effectiveness and safety of the Stem Cell Regenera Treatment for oocyte activation in women with ovarian failure, including conditions such as Poor Ovarian Response (POR), Diminished Ovarian Reserve (DOR), and Premature Ovarian Insufficiency (POI). This retrospective observational study was conducted from January 2023 to December 2024 at the IVIRMA Alicante Clinics in Spain. Women diagnosed with ovarian failure participated in the study, which involved mobilizing Hematopoietic Stem Cells from bone marrow into peripheral blood using granulocyte colony- stimulating factor (G-CSF).

Cryobiology. 2025 Jun;119:105214. Long-term stability of blood-derived eye drops is required to adapt the use of this treatment to prolonged clinical treatments and more green pharmacy. This study has been designed to assess the long-term storage life of freeze-dried plasma rich in growth factors (PRGF) eye drops, maintaining their biological content and activity. Thus, blood from five healthy donors was extracted and centrifuged for obtaining PRGF. The obtained PRGF eye-drops after platelet activation were freeze-stored or were lyophilized and then stored for 18 and 24 months at room temperature (RT) or at + 5 °C. Growth factor content and proliferative potential of PRGF eye drops on primary human keratocytes (HK) was evaluated at each storage time and condition.

J Pharm Bioallied Sci. 2025 May;17(Suppl 1):S952-S955. Platelet-rich plasma (PRP) and Plasma Rich in Growth Factors (PRGF) are promising regenerative therapies aimed at enhancing endometrial thickness and improving in vitro fertilization (IVF) outcomes. This study aims to assess the impact of PRP and PRGF on endometrial development, implantation success, and pregnancy rates in IVF patients. A total of 10 ml of venous blood will be drawn from participants and processed to isolate platelets. PRP will be prepared through centrifugation to concentrate platelets, while PRGF will be generated using a leukocyte-poor method and activated with calcium chloride.

Biomedicines. 2025 May 1;13(5):1105. To evaluate the sterility and biological functionality of platelet lysate eye drops stored in BTI ophthalmic devices for PRGF delivery under different storage conditions and simulated use scenarios.

J Ovarian Res. 2025 Apr 24;18(1):84. The aim of this in vitro short report was to determine whether activation of platelet-rich plasma (PRP) results in differential effects on growth factor release and cell proliferation in reproductive medicine. This study involved PRP from five donors, activated with either CaCl2 (exogenous activation) or type I collagen (mimicking endogenous activation). The release of growth factors (EGF and PDGF-AB) and the proliferative response of human ovarian fibroblasts were analysed. PRP activated with CaCl2 formed stable clots and released statistically significant higher levels of EGF (871 ± 426 pg/mL) and PDGF-AB (26535 ± 6477 pg/mL) compared to collagen-activated PRP (EGF: 141 ± 66 pg/mL, PDGF-AB: 13060 ± 2301 pg/mL). Additionally, CaCl2-activated PRP induced greater proliferation in ovarian fibroblasts (34.90 ± 17.82 ng/mL DNA) than collagen-activated PRP (30.75 ± 18.21 ng/mL DNA).

Pain Ther. 2025 Apr;14(2):675-690. Chronic back pain is a long-lasting disorder that is significantly associated with a reduction in the quality of life. Previously, the efficacy of intradiscal and epidural injections of plasma rich in growth factors (PRGF) was demonstrated at 6 months. The objective of this study was to retrospectively examine the medical records of these patients in order to determine whether the observed improvement at the 6-month follow-up was sustained over time.